Global Stem Cell Technology
Stage
Acquired | AcquiredAbout Global Stem Cell Technology
Global Stem Cell Technology develops blood-derived mesenchymal stem cells for clinical use in animals. On July 27, 2020, Global Stem Cell Technology was acquired by Boehringer Ingelheim, terms of the transaction were not disclosed.
Missing: Global Stem Cell Technology's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Global Stem Cell Technology's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Global Stem Cell Technology Patents
Global Stem Cell Technology has filed 2 patents.
The 3 most popular patent topics include:
- Cell biology
- Clusters of differentiation
- Developmental biology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/6/2013 | 10/13/2020 | Transcription factors, Stem cells, Skeletal system, Developmental biology, Clusters of differentiation | Grant |
Application Date | 12/6/2013 |
|---|---|
Grant Date | 10/13/2020 |
Title | |
Related Topics | Transcription factors, Stem cells, Skeletal system, Developmental biology, Clusters of differentiation |
Status | Grant |
Latest Global Stem Cell Technology News
Sep 3, 2020
Boehringer Ingelheim acquiert la biotech belge Global Stem cell Technology (GST) 03 septembre 2020 Boehringer Ingelheim, dont le siège français est à Lyon , (CA 2019 : 19 Mds / 51 000 salariés dans le monde dont 2 500 en France) et deuxième acteur mondial de la santé animale annonce le rachat de Global Stem cell Technology (GST), société belge de biotechnologie vétérinaire. GST est spécialisée dans la recherche, le développement et la production de médicaments traitant les maladies orthopédiques et métaboliques des animaux. Cette décision de racheter GST s’intègre à la stratégie de Boehringer Ingelheim Santé Animale, visant, dans une dynamique d’innovation et de croissance, à enrichir son portefeuille de solutions thérapeutiques. Dans l’agglomération lyonnaise les investissements cumulés depuis le rachat de Merial par BI s’élèvent à 335 millions d’euros à Lyon Porte des Alpes (135 M€) et 200 M€ à Jonage dans le futur site de production de vaccins vétérinaires contre la fièvre aphteuse et la fièvre catarrhale ovine (mise en service 2021) Pour poursuivre votre lecture, abonnez-vous. -50% sur votre abonnement
Global Stem Cell Technology Frequently Asked Questions (FAQ)
Where is Global Stem Cell Technology's headquarters?
Global Stem Cell Technology's headquarters is located at Noorwegenstraat 4, Evergem.
What is Global Stem Cell Technology's latest funding round?
Global Stem Cell Technology's latest funding round is Acquired.
Who are the investors of Global Stem Cell Technology?
Investors of Global Stem Cell Technology include Boehringer Ingelheim.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.